A report from GHTC and Policy Cures Research examines how US federal funding for global health R&D is delivering impact both abroad and at home.

Search the GHTC website

Research Roundup: Pharmaceutical waste and superbugs, resistance to insecticides, and vaccines for crises

Read time:
David Jacobs

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

October 23, 2016 by Kat Kelley

While overuse of antibiotics is often cited as a leading contributor to the development and spread of drug-resistant bacteria, recent studies reveal that pollution from antibiotic manufacturing plants in India and China is also playing a role. The wastewater released from these manufacturing facilities contains active antimicrobial ingredients, and in some cases, higher concentrations of these compounds are found downstream from these facilities than is found in patients currently taking antibiotics. One type of bacteria can acquire from another type of bacteria genes that confer resistance to a certain drug. Consequently, resistance is spreading rapidly in wastewater treatment plants in China—for every bacterium that goes into the plants, four to five drug-resistant bacteria come out. To combat this dangerous trend, advocates are calling on the US government, drugmakers, pharmaceutical retailers, and consumers to put pressure on these plants to stop polluting using diplomatic tactics and purchasing power.

Meanwhile, new data from the European Medicines Agency indicate that while sales of antibiotics for use in livestock has declined modestly in the European Union, sales have increased for many of the world’s strongest antibiotics, including last-resort treatments and those deemed by the World Health Organization (WHO) to be “critically important in human medicine.”

Between 2000 and 2015, insecticides prevented nearly 500 million deaths from malaria, however, this remarkable progress could be upended as mosquitoes develop resistance to pyrethroids, the most commonly used class of insecticides. Pyrethroids have been around for nearly 40 years, and while resistance to this class first appeared in 1993, it has been growing rapidly over the past decade, which has resulted in increased transmission of the parasite in some countries. The pipeline for new insecticides is limited, particularly those that are safe for use in bednets. IVCC, a public-private partnership and member of GHTC, is catalyzing research to both develop novel insecticides and products that combine pyrethroids with other agents to combat growing resistance. The organization has partnered with several pharmaceutical companies and is screening their libraries of more than 4 million chemical compounds to identify the three most promising, which they will then test to determine not only safety and efficacy, but also whether they are long lasting (i.e., effective for at least three years and able to withstand 20 rounds of washing). Other entities have created bednets that combine pyrethroids with pyriproxyfen—which sterilizes the mosquitoes—and piperonyl butoxide—which could make resistance mosquitoes vulnerable to pyrethroids again. For the former, results from an evaluation will be released shortly, and for the latter, results of small trials have been encouraging, but larger, more rigorous trials are needed.

The WHO recently convened pharmaceutical companies and humanitarian organizations with the goal of establishing a mechanism to facilitate the sale of low-cost vaccines during emergencies. Under the program, pharmaceutical companies would pledge to provide predetermined vaccines at the lowest price possible during crises such as natural disasters or wars. Currently, many of the targeted drugmakers have agreements with Gavi, the Vaccine Alliance, through which vaccines are purchased in high volumes at these rock-bottom prices. However, the proposed mechanism would limit sales to nonprofits, rather than governmental bodies, to ensure that the vaccines procured would only be deployed as part of a crisis response. GlaxoSmithKline has already agreed to participate, providing its vaccine against pneumonia—the leading cause of death for children under five—at a reduced price during emergencies. The WHO is working to engage additional drugmakers as it seeks to expand the mechanism to cover vaccines against 23 different diseases, including cholera, measles, yellow fever, and hepatitis.

Categories: Antimicrobial resistance, Malaria, Vaccines, WHO

About the author

Kat KelleyGHTC

Kat Kelly is a senior program assistant at GHTC who supports GHTC's communications and member engagement activities.

Other Breakthroughs Blog posts you may like:
National Institute of Allergy and Infectious Diseases
October 30, 2016

Research Roundup: Gene editing, mosquito takeover, and decoys for drug resistance

Written by Kat Kelley / GHTC
Read time:
A key target of the HIV virus is immune cells known as T cells. The virus infects T cells and hijacks the cell’s genetic machinery, enabling it to multiply and spread throughout the body. However, some T cells have genetic mutations that protect against HIV infection, and scientists at University of California, San Francisco (UCSF), are using CRISPR—a novel approach to gene editing—to insert these protective genetic mutations into ordinary T cells. First, the team used CRISPR to rapidly identify all T cell genes involved in HIV infection. Next, they inserted 149 different genetic mutations into T cells, 6 of which successfully blocked the virus. Eventually, the researchers hope that one or more of these mutations could be developed into a drug to prevent or treat HIV and AIDS. Biotech company Sangamo Biosciences is currently testing one such gene mutation that in early results appears to lower the viral load of participants. However, other studies suggest that the virus may be able to outsmart this approach, mutating until it is able to infect T cells. Consequently, an effective treatment may need to elicit multiple gene mutations in T cells, either concurrently or sequentially. Over the past five years, the Eliminate Dengue Program has released mosquitoes infected with the innocuous Wolbachia bacteria into small communities in Colombia, Brazil, Vietnam, Indonesia, and Australia. The bacteria colonizes a multitude of insect species, and while it doesn’t harm the Aedes aegypti mosquito—which spreads Zika, dengue, and yellow fever—it does prevent these viruses from replicating and blocks further transmission. Wolbachia is passed down from generation to generation of A. aegypti with each generation only living for a few weeks. Consequently, within weeks of releasing Wolbachia-infected mosquitoes into the wild, disease transmission drops drastically. Now, Eliminate Dengue will be conducting two large-scale trials in Bello, Colombia, and Rio de Janeiro, Brazil, to determine if this approach can successfully combat mosquito-borne illnesses in urban areas home to millions. The trials are funded by the United States and United Kingdom governments and philanthropic organizations the Wellcome Trust and the Bill & Melinda Gates Foundation. The highly drug-resistant Methicillin-resistant Staphylococcus aureus (MRSA) bacteria is only susceptible to a few, last-resort antibiotics, including daptomycin, which is effective against two-thirds of MRSA infections. Now, scientists at Imperial College London have discovered how the remaining one-third of MRSA infections evade antibiotics. The bacterial cells use chemical signals to communicate with one another, however, some cells can shut down this communication system. Once that system is deactivated, the bacterial cells are able to produce decoys—molecules that have a similar outer layer to the bacteria, and consequently are targeted by the antibiotics. Thus, the antibiotics are wasted on the decoy cells and the bacterial cells are able to thrive. These findings could pave the way for new ways to treat MRSA, by combining daptomycin with a drug that interferes with the decoy system. Currently, clinical trials are underway to test such an approach, combining daptomycin with approved and experimental antibiotics that impede either the production or release of decoy molecules.
Army Medicine
October 16, 2016

Research Roundup: Ebola treatment, black widow virus, and Zika syndrome

Written by Kat Kelley / GHTC
Read time:
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week. During the recent Ebola epidemic in West Africa, an experimental drug, ZMapp, showed promise in treating the disease, but with only enough doses to treat seven people, the drug’s true impact remained unknown. Now, results of a randomized control trial conducted during the outbreak indicate that ZMapp likely increases a patient’s chance of survival, but fall just short of statistical significance. The researchers hoped to enroll 200 patients across Liberia, Sierra Leone, and Guinea, however, as the number of new cases waned, so too did eligible participants for the trial. Ultimately, the team recruited only 72 participants, all of whom received the standard care for Ebola and half of whom also received ZMapp. Further complicating the results, many of the patients were enrolled after the virus had already caused irreparable tissue damage and did not survive long enough to receive all three doses of ZMapp. The results suggest high probability—91.2 percent—that ZMapp is effective against the virus and confirm the drug’s safety. ZMapp is composed of three antibodies against Ebola, and research is underway to develop improved antibodies which could enhance the drug’s efficacy. Viruses are constantly mutating, and often incorporate genes from the organisms they infect—viruses that infect bacteria often have bacterial DNA and viruses that infect animals often have animal DNA. The WO virus targets the bacteria Wolbachia, which in turn targets spiders and insects. Consequently, when researchers at Vanderbilt University sequenced the genome of WO, they expected to find snippets of Wolbachia DNA. Instead, they found that one third of WO’s genes came from the arthropods that Wolbachia infects. Further, WO contains genes for latrotoxin, the chemical cornerstone of the venom found in black widow spiders, a particularly surprising discovery as latrotoxin has never been reported outside of spiders. The scientists suspect WO’s unique evolution relied on the way Wolbachia intertwines itself with animal cells, requiring WO to drill through the animal cell membranes to reach the bacteria. Zika virus, first discovered in 1947, was long considered innocuous, rarely reported in humans and associated with a mild infection. The virus raised concern, however, when scientists discovered its connection to microcephaly—a birth defect in which an infant’s brain does not develop properly, resulting in an abnormally small head. Now, one year after a spike in microcephaly cases in Brazil led to this important discovery, infants with what’s been deemed congenital Zika syndrome are coping with a range of devastating symptoms not usually reported in infants with microcephaly, including seizures, impaired vision and hearing, difficulty swallowing, and arm and leg deformities. Additionally, some infants have presented with neurological and physical defects despite having normal-sized heads and others still have developed microcephaly after birth, as the growth of the head has not kept up with that of the body.